Skip to main content
Premium Trial:

Request an Annual Quote

Following Spring Cleaning, Paradigm Genetics Posts Increased Losses, Lower Revenues

NEW YORK, Aug. 12-Paradigm Genetics today reported increased losses and declining revenues for the second quarter of 2002.


Net loss for the quarter was $5 million or $0.16 per share, compared to a net loss of $4.3 million or $0.16 per share in the same quarter of 2001.


Revenues fell by 13 percent to $5.3 million for the quarter from $6.1 million in the first quarter of 2001, a slump caused by a slowdown in Paradigm's commercial partnership with Bayer. The company said this decline was partly offset by new revenues from its December 2001 purchase of the plant genomics firm ParaGen.


Including stock-based compensation expenses, the company spent $7.6 million on R&D in the quarter, up from $6.9 million in the second quarter last year.


As of June 30, 2002, Paradigm held $9.6 million in cash, cash equivalents and short-term investments.


Earlier this spring, Paradigm launched a house-cleaningthat laid off 20 percent of the workforce and replaced founder and CEO John Ryals with Syngenta executive Heinrich Gugger.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.